

1694  
\$

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	09/877,387
	Filing Date	June 7, 2001
	First Named Inventor	David S. JONES
	Art Unit	1624
	Examiner Name	R. L. Raymond
Total Number of Pages in This Submission	10 + 22 refs.	Attorney Docket Number 252312007500

ENCLOSURES (Check all that apply)			
<input checked="" type="checkbox"/> Fee Transmittal Form (1 page + copy)  <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment/Reply  <input type="checkbox"/> After Final  <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input checked="" type="checkbox"/> Information Disclosure Statement (3 pages)  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/ Incomplete Application  <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition  <input type="checkbox"/> Petition to Convert to a Provisional Application  <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC)  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO-1449 (2 pages + copy) Twenty-two (22) Cited References Return Receipt Postcard	
<table border="1"><tr><td>Remarks</td></tr></table>			Remarks
Remarks			

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	MORRISON & FOERSTER LLP (Customer No. 25226) Charles D. Holland - 35,196
Signature	
Date	August 25, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: August 25, 2004	Signature:  (Kerry C. Keehan)



PTO/SB/17 (10-03)

Approved for use through 7/31/2006. OMB 0651-0032  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**FEE TRANSMITTAL  
for FY 2004**

Effective 10/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT (\$)** 180.00**Complete if Known**

Application Number	09/877,387
Filing Date	June 7, 2001
First Named Inventor	David S. JONES
Examiner Name	R. Raymond
Art Unit	1624
Attorney Docket No.	252312007500

**METHOD OF PAYMENT (check all that apply)**☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None☒ Deposit Account:Deposit  
Account  
Number

03-1952

Deposit  
Account  
Name

Morrison &amp; Foerster LLP

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee  
to the above-identified deposit account.**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

**SUBTOTAL (1) (\$)** 0.00**2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE**

	Total Claims	Extra Claims	Fee from below	Fee Paid
Total Claims	95	-95** =	0	0.00
Independent Claims	14	-14** =	0	0.00
Multiple Dependent			145	0.00

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

**SUBTOTAL (2) (\$)** 0.00

\*\*or number previously paid, if greater; For Reissues, see above

**FEE CALCULATION (continued)****3. ADDITIONAL FEES**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180.00
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

\*Reduced by Basic Filing Fee Paid

**SUBTOTAL (3) (\$)** 180.00**SUBMITTED BY**

Name (Print/Type) Charles D. Holland

Registration No.  
(Attorney/Agent)

35,196

(Complete if applicable)

Telephone (650) 813-5832

Signature

Date

August 25, 2004



PATENT  
Docket No. 252312007500

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on August 25, 2004.

Kerry C. Keehan

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

David S. JONES

Serial No.: 09/877,387

Filing Date: June 7, 2001

For: MULTIVALENT PLATFORM  
MOLECULES COMPRISING HIGH  
MOLECULAR WEIGHT  
POLYETHYLENE OXIDE

Examiner: R. Raymond

Group Art Unit: 1624

SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

08/30/2004 HBERHE 00000168 031952 09877387

02 FC:1806 180.00 DA

This Supplemental Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☒ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of \_\_\_ is enclosed.
  - ☒ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of \_\_\_ is enclosed.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)


Applicant would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 252312007500. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: August 25, 2004

Respectfully submitted,

By: 

Charles D. Holland  
Registration No. 35,196

Morrison & Foerster LLP  
755 Page Mill Road  
Palo Alto, California 94304-1018  
Telephone: (650) 813-5832  
Facsimile: (650) 494-0792

Form PTO-1449

Docket Number 252312007500

Application Number 09/877,387

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

Applicant

David S. JONES

Filing Date June 7, 2001

Group Art Unit 1624

Mailing Date August 25, 2004

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	06/08/1999	09/328,199	Marquis et al.			
	2.	04/11/1989	4,820,812	Miyoshi et al.			
	3.	02/27/1990	4,904,582	Tullis			
	4.	04/03/1990	4,913,812	Moriguchi et al.			
	5.	09/19/1995	5,451,576	Sessler et al.			
	6.	02/27/1996	5,495,006	Climie et al.			
	7.	04/09/1996	5,506,110	Matsuura et al.			
	8.	10/22/1996	5,567,422	Greenwald			
	9.	06/04/2002	6,399,578	Jack et al.			

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	10.	11/10/1994	WO 94/25071	WIPO			
	11.	12/27/1996	WO 96/41813	WIPO			

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	12.	Abaza, M-S. I. et al. (1992). "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of Myoglobin," <i>J. of Protein Chemistry</i> 11(5):433-444.
	13.	Aldrich, ed. (2003-2004) <u>Katalog Handbuch Feinchemikalien Und Laborgeräte</u> Deutschland, page 5 (A730-A732); page 386 (38,202-7), page 1320 (55,441-3).
	14.	Boturyn, D. et al. (2004). "Template Assembled Cyclopeptides as Multimeric System for Integrin Targeting and Endocytosis," <i>J. Am. Chem. Soc.</i> 126(18):5730-5739.
	15.	Datta, B. et al. (March 5, 1992). "I. Cross-Linking of U2 snRNA Using Nitrogen Mustard," <i>J. Biol. Chem.</i> 267(7):4497-4502.
	16.	Dintzis, H.M. et al. (October, 1976). "Molecular Determinants of Immunogenicity: The Immunon Model of Immune Response," <i>Proc. Natl. Acad. Sci. USA</i> 73(10):3671-3675.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 252312007500

Application Number 09/877,387

Applicant

David S. JONES

Filing Date June 7, 2001

Group Art Unit 1624

Mailing Date August 25, 2004

**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**

(Use several sheets if necessary)

- |     |                                                                                                                                                                                                                                                                                                               |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 17. | Döring, T. et al. (1991). "The Three-Dimensional Folding of Ribosomal RNA; Localization of a Series of Intra-RNA Cross-Links in 23S RNA Induced by Treatment of <i>Escherichia coli</i> 50S Ribosomal Subunits with <i>bis</i> -(2-chloroethyl)-methylamine," <i>Nucleic Acids Research</i> 19(13):3517-3524. |
| 18. | European Office Action mailed December 8, 2003, for European Application Number 99964209.3, filed December 9, 1999, five pages.                                                                                                                                                                               |
| 19. | Falbe, J. et al. eds. (1990). <u>Rompp Chemie Lexikon</u> George Thieme Verlag: Stuttgart, p. 1614, under "Glycylglycin."                                                                                                                                                                                     |
| 20. | Lehninger, A.L. ed. (1975) <u>Biochemistry</u> , 2nd Edition. Worth Publishers, Inc. pp. 742-743.                                                                                                                                                                                                             |
| 21. | Ngo, J. T. et al. (1994). "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," Chapter 14 <u>In The Protein Folding Problem and Tertiary Structure Prediction</u> , Merz, K. Jr. and Le Grand, S. eds. pp. 433-506.                                                           |
| 22. | Oßwald, M. et al. (1990). "Localization of a Series of RNA-Protein Cross-Link Sites in the 23S and 5S Ribosomal RNA from <i>Escherichia coli</i> , Induced by Treatment of 50S Subunits with Three Different Bifunctional Reagents," <i>Nucleic Acids Research</i> 18(23):6755-6760.                          |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.